Page 45 - Zai Lab News Today

Biotech investors are optimistic about the prospects for a potential treatment.

A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company.

Just because a story is written doesn't mean it's over. Here are some updates on health innovation stories we covered in 2022.

Investors should steer clear of Deciphera shares. Read why the risk/reward profile does not look attractive at this time.

Zai Labs is a relative new entrant to the Chinese pharma space and has multiple approvals and a large clinical pipeline. Read more on ZLAB here.

You may have heard of the VR game Drunk or Dead, which was released on Steam in 2016... So there you have it! Next year, our studio will release a Drunk or Dead 2 demo, which you should definitely check out. Zombies, alcohol, cool weapons, alcohol, co-op...

You may have heard of the VR game Drunk or Dead, which was released on Steam in 2016... So there you have it! Next year, our studio will release a Drunk or Dead 2 demo, which you should definitely check out. Zombies, alcohol, cool weapons, alcohol, co-op...

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity ap...

California Public Employees Retirement System decreased its holdings in shares of Zai Lab Limited (NASDAQ:ZLAB – Get Rating) by 4.2% during the second quarter, HoldingsChannel reports. The fund owned 110,797 shares of the company’s stock after selling 4,819 shares during the quarter. California Public Employees Retirement System’s holdings in Zai Lab were worth $3,842,000 as […]

LONDON and SINGAPORE, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Claritas HealthTech (“Claritas”), a healthcare technology company specializing in medical image...